The Latest Cardiac and Vascular News
ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ — Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics’ SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal […]
ABBOTT PARK, Ill., Jan. 11, 2018 – Abbott today announced CE Mark approval for the company’s new Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, a product designed to advance cardiac mapping during cardiac ablation to treat patients with complex cardiac arrhythmias. With the European launch of this latest addition to […]
ABBOTT PARK, Ill., Dec. 15, 2017 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today increased the company’s quarterly common dividend to 28 cents per share from 26.5 cents per share. This marks the 376th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2018, to shareholders of record at […]
ABBOTT PARK, Ill., Nov. 6, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the company’s MitraClip device for treatment of people with mitral regurgitation (MR), a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward […]
DENVER, Oct. 30, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary artery disease had the same long-lasting health outcomes at three years but felt better more quickly than patients who underwent open-heart surgery. The data were presented during […]
ABBOTT PARK, Ill., Oct. 23, 2017 /PRNewswire/ — Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx™ Insertable Cardiac Monitor (ICM), the world’s first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias. With FDA clearance Abbott can now provide U.S. patients a new […]
ABBOTT PARK, Ill., Sept. 22, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of Abbott’s most widely-used implantable cardioverter defibrillators (ICD) and associated high voltage leads. The approval of MR-conditional labeling for the Ellipse ICD with the Tendril MRI […]
Time to throw in the towel for Abbott on this generation of their Absorb BVS because of slow sales. However, there could still be a platform for this technology… Abbott halts global sales of 1st-gen Absorb stents SEPTEMBER 8, 2017 BY FINK DENSFORD , MassDevice Abbott (NYSE:ABT) said today it will halt global sales […]
ABBOTT PARK, Ill., Aug. 29, 2017 – Today, Abbott notified physicians of updates to its implantable pacemakers and defibrillators as part of its ongoing commitment to continuously improve patient care. The new device updates include a Battery Performance Alert for our implantable cardioverter defibrillators (ICDs) that provides physicians with earlier […]
ABBOTT PARK, Ill., Aug. 28, 2017 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system provides a new option for physicians managing advanced heart failure patients in need […]
